Disc Medicine announced it will present data from several clinical trials at the European Hematology Association (EHA) 2026 Congress, including an oral presentation of the RALLY-MF phase 2 trial of DISC-0974 for anemia in myelofibrosis. The trial showed a 70% overall response rate across different patient groups, regardless of JAK inhibitor use. Additional updates will cover bitopertin studies in erythropoietic protoporphyria (EPP) and the ongoing DISC-3405 trial for polycythemia vera. A corporate update call is scheduled for June 15 to discuss the data and next steps.
Last week, large-cap technology and AI-related stocks led Wall Street's top gainers, driven by strong earnings reports, positive guidance, and analyst upgrades. Companies like Tower Semiconductor, Venture Global, and Palo Alto Networks saw significan...
Taiwan Semiconductor Manufacturing Co. announced a $31.28 billion capital expenditure plan to expand its advanced chip manufacturing capabilities. This move aims to meet rising global demand driven by artificial intelligence, 5G, and high-performance...
Last week, large-cap stocks in sectors like housing, nuclear energy, crypto mining, and global commodities experienced significant declines due to earnings volatility, rising Treasury yields, geopolitical tensions in the Middle East, and weaker crypt...
The US Dollar and Brent crude oil prices have shown an unusual positive correlation of 0.55, the highest since 2005, coinciding with the Iran war's onset in March 2026. Typically, these move inversely because oil is priced in US Dollars, but geopolit...
Ray Dalio, founder of Bridgewater Associates, expressed concerns about the declining global influence of the United States amid China's growing economic power, now estimated at 60-70% of the US economy. After spending significant time in Asia, Dalio ...
